webinar register page

Webinar banner
Accelerate your Translational Research with NCRIS
In the 2022-23 Round 2 Pipeline Accelerator round, we are partnering with Phenomics Australia to expand the list of translation expertise necessary for the discovery and translation of medical research. This webinar will outline how researchers from the public and private sectors can apply for vouchers to gain additional subsidised access to a range of research infrastructure facilities including Phenomics Australia's.

PROGRAM
1. Welcome to Country
2. The voucher scheme
3. Introduction to NCRIS Health Group
4. Capability Introduction - TIA and Phenomics Australia
5. Q&A

01:06:00

Webinar logo
* Required information
Loading
Register

Speakers

Dr Stuart Newman
CEO @Therapeutic Innovation Australia
Since completing a PhD in Antarctic Biology from the University of Tasmania, Stuart has built up considerable experience of science policy, pharmaceutical R&D, grant funding, IP management, business development and commercialisation in the university and not-for-profit sectors. ​ Stuart joined TIA as CEO in 2017. Under his leadership, TIA has focussed investment on the gap between research and development of high-value therapeutics, including pharmaceuticals, biologics, vaccines and cell & gene therapies. He also devised an innovative infrastructure access voucher scheme. He is a graduate of the Australian Institute of Company Directors.
Dr Michael Dobbie
CEO @Phenomics Australia
Dr Michael Dobbie has worked to establish and operate Phenomics Australia since its foundation in 2007, serving as CEO since 2013. Prior to leading the development and implementation of these national research infrastructures, Michael was a biomedical research with a PhD in Neurochemistry from the University of London and gained over 20 Years’ experience at the bench in field including genetics, vascular biology, cancer angiogenesis, neuroscience, metabolism, developmental biology, malaria and oxidative stress.
Mr Ben Hughes
Director of Strategic Development, National Biologics Facility @Therapeutic Innovation Australia
Ben brings over 20 years of experience in commercializing biologics with a proven track record of developing successful teams and implementing compliant systems for cGMP manufacturing in both Australia and the US. Ben has extensive experience in facility design and start-up, and delivering for his customers in bringing a broad range of vaccines and biologics products through tech transfer from process development through to GMP manufacture and commercialization. Ben previously worked at Patheon by Thermo Fisher, The University of Queensland, Merck and Co, Inc., and CSL, and is a graduate of the University of New South Wales Bioprocess (Chemical) Engineering.
Dr Heather Donaghy
Scientific Engagement Manager, Cell and Gene Therapies Capability @Therapeutic Innovation Australia
Heather completed her PhD in viral immunology at Imperial College before moving to Sydney for a post-doc at Westmead. Since then she has had a career spanning basic science, preclinical and clinical research in immunology and oncology. ​ Heather has a track record of enabling and developing research programs including proof of concept studies and commercially successful projects. Heather works with researchers to understand their unique circumstances. She has diverse project management expertise, from planning and executing preclinical studies to database migration. ​ Heather brings her diverse experience to TIA to enable researchers within the cell and gene space to access manufacturing facilities and enhance translation of novel therapies to the clinic.
Dr John Parisot
Business Development Manager, Small Molecule Therapeutics Capability @Therapeutic Innovation Australia
In addition to John's role at TIA, he is also the Strategic Partnerships Advisor for Phenomics Australia and Bioplatforms Australia. John has over 20 years’ experience in human based healthcare R&D for pharmaceutical companies, biotech’s and world leading academic institutes. He is an experienced stakeholder manager and collaborator who has succeeded in early stage drug development and clinical trials management gaining a comprehensive understanding of the path to market for new drug entities. Project management from high throughput drug discovery for multiple diseases encompassing cancer, tropical diseases and immunotherapeutic targets, through to clinical trials with a deep understanding of the pre-clinical to regulatory pathways to develop new therapies for approval by the TGA & FDA.

Share via Email

All fields are required
 

Switch Time Zone